A recent study by Yue et al. demonstrated that through the alteration of miR-124, AD-related BACE1 levels declined when lncRNA XIST was silenced, suggesting this lncRNA as a potential therapeutic target for AD [80]. Here, BACE1 is linked to Alzheimer disease.